AstraZeneca PLC and Myriad Genetics, Inc. Release: Patients Begin Enrolling in Studies to Determine if Women With BRCA 1 & 2 Positive Cancer may Receive Greater Benefit From New Treatment

ALDERLEY PARK, England, June 19 /CNW/ - AstraZeneca (NYSE: AZN) today announced the start of two Phase II trials for a new compound being tested to treat patients with BRCA 1 & 2 positive breast and ovarian cancer. Myriad Genetics, Inc. (Nasdaq: MYGN, www.myriad.com), is providing the molecular diagnostic testing (BRACAnalysis(TM)) for these trials.